Sugi Predict

Sugi Predict / Compounds / SCHEMBL1475902

SCHEMBL1475902

SCHEMBL1475902

CN1CCC(c2nc(-c3ccc(C(=O)O)cc3)cs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.55
▸ CTSB P07858 1/20 0.55
▸ CTSS P25774 1/20 0.55
▸ KDM4E B2RXH2 5/20 0.52
▸ RAB9A P51151 5/20 0.52
▸ GAA P10253 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ ALDH1A1 P00352 6/20 0.51
▸ CPT2 P23786 1/20 0.49
▸ CPT1A P50416 1/20 0.49
▸ CPT1B Q92523 1/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ NPC1 O15118 4/20 0.48
▸ CHEK1 O14757 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ FAAH O00519 1/20 0.45
▸ SCN9A Q15858 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480507 0.93 KDM4E (0.50) CTSLCTSBCTSSKDM4ERAB9A
SCHEMBL1474426 0.82 HPGDS (0.60) KDM4ERAB9AGAAPOLBHTT
SCHEMBL21774252 0.79 SMN1; SMN2 (0.54) CTSLCTSBCTSSKDM4ERAB9A
SCHEMBL5113276 0.78 NPC1 (0.51) CTSLCTSBCTSSRAB9ASMN1; SMN2
SCHEMBL25168713 0.78 FAAH (0.51) RAB9ASMN1; SMN2NPC1FAAHL3MBTL1
SCHEMBL10253093 0.77 CASP8 (0.42) CTSLCTSBCTSSALDH1A1L3MBTL1
SCHEMBL1169212 0.77 CHEK1 (0.58) CTSLCTSBCTSSKDM4ERAB9A
SCHEMBL18711879 0.76 FAAH (0.59) ALDH1A1SMN1; SMN2FAAHSCN9AL3MBTL1
Bromide SCHEMBL1146428 0.76 CHEK1 (0.57) CTSLCTSBCTSSKDM4ERAB9A
SCHEMBL3763231 0.75 FAAH (0.61) ALDH1A1CPT1ASMN1; SMN2FAAHSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150209349-A1 Piperazine Compounds AMURA THERAPEUTICS LTD (GB) 2015-07-30 — — US disclosed
EP-2240491-B1 TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES AMURA THERAPEUTICS LTD (GB) 2015-07-15 — — EP disclosed
US-9045492-B2 Piperazine compounds AMURA THERAPEUTICS LIMITED (GB) 2015-06-02 — — US disclosed
US-8877927-B2 Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors GRUNENTHAL GMBH (DE) 2014-11-04 — — US disclosed
EP-2719700-A1 TETRAHYDROFURO(3,2-B)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES Amura Therapeutics Limited (GB) 2014-04-16 — — EP disclosed
US-20130252969-A1 Compounds AMURA THERAPEUTICS LIMITED (GB) 2013-09-26 — — US disclosed
US-8501744-B2 Piperazine compounds AMURA THERAPEUTICS, LIMITED (GB) 2013-08-06 — — US disclosed
EP-2078023-B1 TETRAHYDROFURO (3, 2-B) PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES AMURA THERAPEUTICS LTD (GB) 2012-12-26 — — EP disclosed
EP-2046797-B1 FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LTD (GB) 2012-05-23 — — EP disclosed
US-20110112089-A1 Cysteine Protease Inhibitors MEDIVIR AB (SE) 2011-05-12 — — US disclosed
US-20080234260-A1 Cysteine Protease inhibitors MEDIVIR AB (SE) 2008-09-25 — — US disclosed
US-20080234260-A1 Cysteine Protease inhibitors MEDIVIR AB (SE) 2008-09-25 — — US disclosed
WO-2005066180-A9 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-09-25 — — WO disclosed
WO-2008007127-A1 FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2008007107-A1 TETRAHYDROFURO (3, 2-B) PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
CN-1918169-A Cysteine protease inhibitors MEDIVIR AB (SE) 2007-02-21 — — CN disclosed
WO-2007006714-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2007-01-18 — — WO disclosed
WO-2007006714-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2007-01-18 — — WO disclosed
EP-1701960-A1 CYSTEINE PROTEASE INHIBITORS Medivir Aktiebolag (SE) 2006-09-20 — — EP disclosed
WO-2005066180-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2005-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234260-A1 Cysteine Protease inhibitors CTSS, CTSZ, CTSK CTSL 10/4885CTSB 7/4885CTSS 1/4885
US-20150209349-A1 Piperazine Compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 CTSL 2905/4885CTSB 4224/4885CTSS 3859/4885
US-20130252969-A1 Compounds CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 CTSL 2921/4885CTSB 4044/4885CTSS 3908/4885
US-20110112089-A1 Cysteine Protease Inhibitors CTSS, CTSZ, CTSK CTSL 11/4885CTSB 7/4885CTSS 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.